Navigation Links
OICR Makes Equity Investment in Medical Information Company
Date:10/12/2010

TORONTO, Oct. 12 /PRNewswire/ -- The Ontario Institute for Cancer Research (OICR) today announced it has made an equity investment in Privacy Analytics Inc., an Ontario company that is developing a software platform to help organizations such as health centers disclose detailed disease and treatment data without compromising individual privacy.

The software platform, called Privacy Analytics Risk Assessment Tool (PARAT), is currently being used by hospitals and patient registries in Canada. The funding from OICR will be used to extend the functionality of PARAT to include more powerful capabilities.

"With the increasing volumes of personal health data being collected today, there are rising demands to use that data for multiple purposes, including trend detection, public health monitoring of diseases such as cancer, and predictive modeling," said Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of OICR. "However, the breach of personal information can often result in costly legislative action, litigation and reputational damage, all of which can cripple an organization.  PARAT protects individual privacy while unlocking the potential of vast amounts of data on diseases and patient care."

"The current approaches for dealing with privacy in medical data result in excessive distortion of the information," said Dr. Khaled El Emam, from the University of Ottawa, who is serving as the lead investigator for OICR for the application of PARAT technology. "The PARAT software will address this shortcoming, permitting more sophisticated and accurate analyses of health data for multiple purposes while protecting patient identity."

PARAT is a Windows based application and is compatible with a number of databases (Oracle, Microsoft SQL Server). Using a simple four-step process, PARAT allows for easy and safe disclosure of data. The funding from OICR will also be used to support the marketing and sales of the improved PARAT software into new markets.

Funding from OICR is provided through its Intellectual Property Development and Commercialization Program, which provides seed funding for late stage academic projects that meet specific market-oriented criteria. The PARAT technology was chosen for funding in part because it advances OICR's commitment to the prevention, early detection, diagnosis and treatment of cancer.

About OICR

OICR, based in Ontario, Canada, is a new, innovative cancer research & development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR has 300 scientific staff (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

For more information, please visit the website at www.oicr.on.ca/commercialization.


'/>"/>
SOURCE The Ontario Institute for Cancer Research
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SciQuest Makes the Inc. 500
2. 5000 List of Fastest-Growing Companies for Fourth Consecutive Year
3. Continued Demand Makes Monsanto and Agriculture Unique Investment Opportunities, Global Seeds and Traits Lead to Tell Investors
4. New method makes vaccines stable at tropical temperatures
5. Ethanol Blend Reduction in Brazil Makes Sense Provided 90-Day Deadline is Respected, Says Brazilian Sugarcane Industry Association
6. Woman Owned Business President Makes Her Mark at Professional Reprographics
7. U of A led team makes breakthrough demonstration of pH-regulating protein
8. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
9. Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins
10. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
11. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., a ... fast growing biotech companies, announced today the appointment ... Strategic Advisor. Jim brings nearly 25 years of ... procurement, having spent nearly two decades in executive ... and Procurement at Genzyme and, most recently headed ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Cenna Bioscience ... for the treatment of Alzheimer’s disease, announced today it has been selected to present ... at the Breakers in Palm Beach, Florida. The purpose of the Forum is ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):